Target Name: RASD2
NCBI ID: G23551
Review Report on RASD2 Target / Biomarker Content of Review Report on RASD2 Target / Biomarker
RASD2
Other Name(s): Rhes | Tumor endothelial marker 2 | RHES_HUMAN | GTP-binding protein Rhes | RASD family member 2 | tumor endothelial marker 2 | Ras homolog enriched in striatum | TEM2 | RASD2 variant 1 | MGC:4834

Understanding The Functions of RASD2: Potential Drug Targets

RNA-associated protein 2 (RASD2), also known as RASD2, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the RAS (Ras-associated protein) family, which includes proteins that are involved in cell signaling pathways. RASD2 is a 21-kDa protein that is expressed in the brain, heart, liver, and other tissues. It is involved in a number of different cellular processes, including cell signaling, cell adhesion, and inflammation.

One of the key functions of RASD2 is its role in cell signaling. RASD2 is involved in the formation of the protein complex known as the RAS-Raf-MEK signaling pathway. This pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. RASD2 is thought to play a key role in the regulation of this pathway by allowing the formation of the protein complex that is necessary for the activity of the RAS-Raf-MEK kinase.

Another function of RASD2 is its role in cell adhesion. RASD2 is involved in the formation of tight junctions, which are a type of cell-cell adhesion structure that helps to maintain the integrity of tissues. RASD2 is thought to play a key role in the regulation of tight junction formation by interacting with the protein known as Zinc Finger N-Endonuclease (ZFN).

In addition to its role in cell signaling and cell adhesion, RASD2 is also involved in the regulation of inflammation. RASD2 is a known regulator of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation. RASD2 is thought to play a key role in the regulation ofNF-kappa-B signaling by interacting with the protein known as IkBKG1.

Despite its involvement in many important cellular processes, RASD2 is not well understood. little is known about the specific functions of RASD2, and much of the research on RASD2 has been done in the past to study its role in cancer.

Recent studies have identified potential drug targets for RASD2. One of the most promising targets is the protein known as S688, which is a known interactor of RASD2. Studies have shown that the addition of S688 to RASD2 causes a significant reduction in the activity of RASD2, suggesting that S688 may be a useful inhibitor of RASD2's activity.

Another potential drug target for RASD2 is the protein known as MDM2, which is a known inhibitor of RASD2. Studies have shown that the addition of MDM2 to RASD2 causes a significant increase in the activity of RASD2, suggesting that MDM2 may be a useful activator of RASD2's activity.

In conclusion, RASD2 is a protein that is involved in a number of different cellular processes throughout the body. Its functions include cell signaling, cell adhesion, and inflammation. Recent studies have identified potential drug targets for RASD2, including the protein known as S688 and the protein known as MDM2. Further research is needed to fully understand the role of RASD2 and its potential as a drug target.

Protein Name: RASD Family Member 2

Functions: GTPase signaling protein that binds to and hydrolyzes GTP. Regulates signaling pathways involving G-proteins-coupled receptor and heterotrimeric proteins such as GNB1, GNB2 and GNB3. May be involved in selected striatal competencies, mainly locomotor activity and motor coordination

The "RASD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RASEF | RASGEF1A | RASGEF1B | RASGEF1C | RASGRF1 | RASGRF2 | RASGRP1 | RASGRP2 | RASGRP3 | RASGRP4 | RASIP1 | RASL10A | RASL10B | RASL11A | RASL11B | RASL12 | RASSF1 | RASSF10 | RASSF2 | RASSF3 | RASSF4 | RASSF5 | RASSF6 | RASSF7 | RASSF8 | RASSF8-AS1 | RASSF9 | RAVER1 | RAVER2 | RAX | RAX2 | RB1 | RB1-DT | RB1CC1 | RBAK | RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A